Immunotherapy for cancer treatment

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immunotherapy modulates immune responses for treating autoimmune diseases, immunodeficiencies, and cancer.
• Cancer immunotherapy utilizes the body's anti-tumor response for novel treatment strategies.
• It involves stimulating or suppressing the immune system to combat diseases.

Purpose of the Study:

• To review current advancements in cancer immunotherapy.
• To discuss adoptive cell therapy, including chimeric antigen receptor T-lymphocytes for hematological cancers.
• To explore immune checkpoint blockade using monoclonal antibodies against CTLA-4 and PD-1.

Main Methods:

• Literature review of cancer immunotherapy strategies.
• Analysis of adoptive cell therapy, focusing on CAR T-lymphocytes.
• Examination of immune checkpoint blockade mechanisms (CTLA-4, PD-1).
• Review of tumor vaccines and monoclonal antibodies (mAbs) in cancer treatment.
• Discussion of mAb-mediated tumor destruction and anti-angiogenesis.

Main Results:

• Adoptive cell therapy, particularly CAR T-cells, shows promise for hematological cancers.
• Immune checkpoint blockade (anti-CTLA-4, anti-PD-1) enhances anti-tumor immune response.
• Monoclonal antibodies can target tumor cells directly or inhibit tumor growth by blocking angiogenesis.

Conclusions:

• Cancer immunotherapy offers promising alternatives to traditional treatments.
• Targeting immune checkpoints and utilizing cell-based therapies represent significant progress.
• Monoclonal antibodies provide versatile therapeutic approaches for cancer treatment.